5-fluorouracil • Lenvima (lenvatinib) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • Stivarga (regorafenib) • oxaliplatin • Qibeian (iparomlimab/tuvonralimab)

CHANCE2202: TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC (clinicaltrials.gov)

P=N/A, N=941, Completed, Zhongda Hospital | Recruiting --> Completed | N=220 --> 941 | Trial completion date: Sep 2023 --> Sep 2025

5 days ago

Trial completion • Enrollment change • Trial completion date

Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • sorafenib • Tyvyt (sintilimab) • Lenvima (lenvatinib) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • AiTan (rivoceranib) • Zepsun (donafenib)

Efficacy and Safety Comparison Between PD-1 Inhibitor Combined With Lenvatinib or With Regorafenib For UHCC After Failure of First-line Treatment (clinicaltrials.gov)

P=N/A, N=200, Completed, Sun Yat-sen University

5 days ago

New trial

Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Tyvyt (sintilimab) • Lenvima (lenvatinib) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • Stivarga (regorafenib)

CHANCE2201: TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC (clinicaltrials.gov)

P=N/A, N=1244, Completed, Zhongda Hospital | Recruiting --> Completed | N=474 --> 1244

5 days ago

Trial completion • Enrollment change

PD-1 Monoclonal Antibody Combined With Gemcitabine and Cisplatin Followed by Selective Radiotherapy for Unresectable Locally Recurrent NPC (clinicaltrials.gov)

P2, N=86, Not yet recruiting, Sun Yat-sen University

8 days ago

New P2 trial

cisplatin • gemcitabine • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr)

A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer (clinicaltrials.gov)

P2, N=44, Recruiting, Chinese PLA General Hospital

8 days ago

New P2 trial • pMMR

AiRuiKa (camrelizumab) • capecitabine • oxaliplatin

Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer (clinicaltrials.gov)

P2, N=44, Not yet recruiting, Guangdong Provincial People's Hospital

8 days ago

New P2 trial • pMMR

AiRuiKa (camrelizumab) • capecitabine • Onivyde (nanoliposomal irinotecan)

13d

Hepatocellular carcinoma with renal invasion and its multimodal management: a rare case report. (PubMed, Front Oncol)

Treatment involved a multimodal strategy combining transarterial chemoembolization (TACE), fractionated radiotherapy, and combination immunotherapy with camrelizumab plus apatinib. This case highlights the rare entity of direct renal invasion from HCC and provides practical insights into its diagnosis and comprehensive management. It illustrates the clinical feasibility and potential benefit of a combined locoregional and systemic strategy in advanced HCC with such uncommon extrahepatic renal involvement, underscoring the importance of individualized treatment in these complex presentations.

13 days ago

Journal

AFP (Alpha-fetoprotein)

AFP elevation

AiRuiKa (camrelizumab) • AiTan (rivoceranib)

19d

Comparison of the 3 Most Commonly Used Modified PD-1 Inhibitors Plus Chemotherapy in Inoperable Wild-Type Non-Small Cell Lung Cancer. (PubMed, Oncology (Williston Park))

Although survival outcomes were comparable among the 3 PD-1 inhibitors in the overall cohort, tislelizumab and sintilimab showed superior PFS in PD-L1-positive subgroups, suggesting biomarker-driven therapeutic selection. These findings underscore the importance of PD-L1 status in optimizing immunotherapy regimens for advanced NSCLC, offering clinical insights for personalized treatment strategies.

19 days ago

Clinical • Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1)

PD-L1 expression

Tyvyt (sintilimab) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr)

19d

FUSCC Refractory TNBC Platform Study (FUTURE2.0) (clinicaltrials.gov)

P2, N=120, Recruiting, Fudan University

19 days ago

Trial completion date • Trial primary completion date

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)

HER-2 negative • ER negative

everolimus • AiRuiKa (camrelizumab) • trastuzumab rezetecan (SHR-A1811) • famitinib (SHR 1020)

20d

Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC Patients (clinicaltrials.gov)

P2, N=41, Completed, Fudan University | Active, not recruiting --> Completed

20 days ago

Trial completion

Erbitux (cetuximab) • cisplatin • AiRuiKa (camrelizumab) • albumin-bound paclitaxel